Femia Alisa, Klein Peter A
Dermatol Online J. 2010 Apr 15;16(4):15.
Lipomas are common benign neoplasms of adipose tissue. Lipomatosis, the progressive appearance of multiple lipomas, is most often associated with specific congenital, familial, or idiopathic syndromes. In one reported case, the development of multiple lipomas occurred as a result of treatment with rosiglitazone, a peroxisome proliferator-activated receptor (PPAR) gamma agonist. We report a second case of lipomatosis occurring as a result of treatment with a PPAR gamma agonist. This case occurred in a 77-year-old woman who developed multiple lipomas two years after beginning treatment with pioglitazone, a PPAR gamma agonist. Histopathologic examination confirmed these lesions to be lipomas. Within four weeks of discontinuation of pioglitazone, regression of the lipomas began. We describe a case of PPAR agonist-induced lipoma formation, review relevant literature, and provide a molecular mechanism for this side effect.
脂肪瘤是常见的脂肪组织良性肿瘤。脂肪瘤病，即多发性脂肪瘤的逐渐出现，最常与特定的先天性、家族性或特发性综合征相关。在一例报告病例中，多发性脂肪瘤的发生是由于使用罗格列酮（一种过氧化物酶体增殖物激活受体 (PPAR)γ 激动剂）进行治疗所致。我们报告了第二例因使用 PPARγ 激动剂而发生脂肪瘤病的病例。该病例发生在一名 77 岁女性身上，她在开始使用 PPARγ 激动剂吡格列酮治疗两年后出现了多发性脂肪瘤。组织病理学检查证实这些病变为脂肪瘤。在停用吡格列酮四周内，脂肪瘤开始消退。我们描述了一例 PPAR 激动剂诱导的脂肪瘤形成病例，回顾了相关文献，并提供了这种副作用的分子机制。
